4.Syed, et al Human epidermal growth receptor-2overexpressing early operable primary breast
cancers in older (>ou=70 ans) women:biology and clinical outcome in comparison with younger
(<70ans) patients. Annals of oncol25 : 837-842 2014
5.Brunello et al, Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk
breast cancer: a retrospective analysis of 260 patients. ,
1T
2005 Aug;16(8):1276-82
6.G Fyfe, R Mass, M Murphy, D Slamon - European Journal of Cancer, 2001
et al, Use of trastuzumab for HER2-positive metastatic breast cancer in daily
practice: a population-based study focusing on the elderly.
T
1T23T
2015
1T23T
1T
Oct 15.
8.Miles D,et al Treatment of older patients with HER2-positive metastatic breast cancer with
pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind,
placebo-controlled phase III trial (CLEOPATRA)
2013 Nov;142(1):89-99.
et al Trastuzumab emtansine in human epidermal growth factor receptor 2-positive
metastatic breast cancer: an integrated safety analysis.
1T
2014 Sep 1;32(25):2750-7
10.Cetin et al. Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly
Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience. ,
1T23T
2013
1T23T
1T
Mar;8(1):67-70
1
t alTrastuzumab plus anastrozole versus anastrozole alone for the treatment of
postmenopausal women with human epidermal growth factor receptor 2-positive, hormone
receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
1T
2009 Nov 20;27(33):5529-37
12.Johnston S et al Lapatinib combined with letrozole versus letrozole and placebo as first line
therapy for postmenopausal hormone receptor positive metastatic breast cancer JCO vol27 -33-
5538-5546 2009
13.Kaufman P, et al Treatment patterns and clinical outcomes in elderly patients with HER2-positive
metastatic breast cancer from the registHER observational study Breast Cancer Res Treat. 2012 Oct;
135(3): 875–883.
